Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed Oct 14, 2021. Long positions only.
- Positions
- 31
- No 13F data for Q4 2020
- Portfolio value
- $251.0M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SNCEScience 37 Holdings, Inc. | COM | 100,000 | $1.01M | 0.4% | – | – | History |
| MGNXMacrogenics Inc | COM | 46,630 | $1.49M | 0.6% | – | – | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.64M | 1.1% | – | – | – |
| MCRBSeres Therapeutics, Inc. | COM | 141,303 | $2.91M | 1.2% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 185,781 | $3.10M | 1.2% | – | – | History |
| IVAInventiva S.A. | ADS | 262,658 | $3.86M | 1.5% | – | – | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $4.11M | 1.6% | – | – | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 97,143 | $4.24M | 1.7% | – | – | History |
| EPIXESSA Pharma Inc. | COM NEW | 176,821 | $5.14M | 2.0% | – | – | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 236,500 | $5.29M | 2.1% | – | – | History |
| XENEXenon Pharmaceuticals Inc. | COM | 301,392 | $5.39M | 2.1% | – | – | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 214,467 | $5.51M | 2.2% | – | – | History |
| RLMDRelmada Therapeutics, Inc. | COM | 161,565 | $5.69M | 2.3% | – | – | History |
| DYNDyne Therapeutics, Inc. | COM | 430,112 | $6.68M | 2.7% | – | – | History |
| MREOMereo BioPharma Group plc | SPON ADS | 2,048,757 | $6.90M | 2.8% | – | – | History |
| MRSNMersana Therapeutics, Inc. | COM | 429,228 | $6.95M | 2.8% | – | – | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 369,951 | $7.62M | 3.0% | – | – | History |
| GNCAGenocea Biosciences, Inc. | COM NEW | 2,871,624 | $7.78M | 3.1% | – | – | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 3,729,694 | $7.94M | 3.2% | – | – | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 795,868 | $8.55M | 3.4% | – | – | – |
| CNSTConstellation Pharmaceuticals Inc | COM | 368,448 | $8.62M | 3.4% | – | – | History |
| KRONKronos Bio, Inc. | COM | 298,839 | $8.75M | 3.5% | – | – | History |
| PTGXProtagonist Therapeutics, Inc | COM | 349,600 | $9.05M | 3.6% | – | – | History |
| ISEEIVERIC bio, Inc. | COM | 1,729,041 | $10.7M | 4.3% | – | – | History |
| COGTCogent Biosciences, Inc. | COM | 1,269,195 | $11.1M | 4.4% | – | – | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 2,983,513 | $13.5M | 5.4% | – | – | History |
| Five Prime Therapeutics Inc33830X104 | COM | 361,344 | $13.6M | 5.4% | – | – | – |
| STSASatsuma Pharmaceuticals, Inc. | COM | 2,431,705 | $14.4M | 5.7% | – | – | History |
| KURAKura Oncology, Inc. | COM | 521,555 | $14.7M | 5.9% | – | – | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 481,094 | $17.8M | 7.1% | – | – | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,028,084 | $25.9M | 10.3% | – | – | History |